Nan Doyle MS

Nan Doyle is a licensed, board-certified genetic counselor who brings perspective from successful corporate, program, philanthropic, and patient engagement roles with Takeda Pharmaceuticals. She is involved in several initiatives, including the Alnylam ActTM-sponsored genetic testing program, which is designed to remove diagnosis as a barrier to the treatment of rare diseases. Before joining Alnylam, Nan was the inaugural Director of Strategic Partnerships and Development for Pathology at Massachusetts General Hospital. She is a licensed, board-certified genetic counselor who brings perspective from successful business and philanthropic development roles with Genzyme Corporation, the Boston Museum of Science, Harvard Medical School, and PAREXEL International Corporation.